This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 119/15/2069    most recent CIRCULATIONAHA.108.803916v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van der Meer, R. W. Articles by Diamant, M. Search for Related Content PubMed PubMed Citation Articles by van der Meer, R. W. Articles by Diamant, M. Related Collections Contractile function Cardiovascular Pharmacology Cardiovascular imaging agents/Techniques Energy metabolism Type 2 diabetes Nuclear cardiology and PET Related Article

(Circulation. 2009;119:2069-2077.)
© 2009 American Heart Association, Inc.

Imaging

Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus

Rutger W. van der Meer, MD, PhD^*; Luuk J. Rijzewijk, MD^*; Hugo W.A.M. de Jong, PhD; Hildo J. Lamb, MD, PhD; Mark Lubberink, PhD; Johannes A. Romijn, MD, PhD; Jeroen J. Bax, MD, PhD; Albert de Roos, MD, PhD; Otto Kamp, MD, PhD; Walter J. Paulus, MD, PhD; Robert J. Heine, MD, PhD; Adriaan A. Lammertsma, PhD; Johannes W.A. Smit, MD, PhD; Michaela Diamant, MD, PhD

From the Department of Radiology (R.W.v.d.M., H.J.L., A.d.R.), Department of Endocrinology (J.A.R., J.W.A.S.), Department of Radiology and Nuclear Medicine (H.W.A.M.d.J.), and Department of Cardiology (J.J.B.), Leiden University Medical Center, Leiden, the Netherlands; the Diabetes Center (L.J.R., R.J.H, M.D.), Department of Cardiology (O.K.), Department of Physiology (W.J.P.), and Department of Nuclear Medicine and PET Research (H.W.A.M.d.J., M.L., A.A.L.), VU University Medical Center, Amsterdam, the Netherlands; and Eli Lilly and Company, Indianapolis, Ind (R.J.H.).

Correspondence to Dr M. Diamant, Diabetes Center, VU University Medical Center, PO Box 7057, 1007 MB Amsterdam, the Netherlands. E-mail m.diamant{at}vumc.nl

Received July 1, 2008; accepted January 27, 2009.

Background— Cardiac disease is the leading cause of mortality in type 2 diabetes mellitus (T2DM). Pioglitazone has been associated with improved cardiac outcome but also with an elevated risk of heart failure. We determined the effects of pioglitazone on myocardial function in relation to cardiac high-energy phosphate, glucose, and fatty acid metabolism and triglyceride content in T2DM patients.

Methods and Results— Seventy-eight T2DM men without structural heart disease or inducible ischemia as assessed by dobutamine stress echocardiography were assigned to pioglitazone (30 mg/d) or metformin (2000 mg/d) and matching placebo for 24 weeks. The primary end point was change in cardiac diastolic function from baseline relative to myocardial metabolic changes, measured by magnetic resonance imaging, proton and phosphorus magnetic resonance spectroscopy, and [¹⁸F]-2-fluoro-2-deoxy-D-glucose and [¹¹C]palmitate positron emission tomography. No patient developed heart failure. Both therapies similarly improved glycemic control, whole-body insulin sensitivity, and blood pressure. Pioglitazone versus metformin improved the early peak flow rate (P=0.047) and left ventricular compliance. Pioglitazone versus metformin increased myocardial glucose uptake (P<0.001), but pioglitazone-related diastolic improvement was not associated with changes in myocardial substrate metabolism. Metformin did not affect myocardial function but decreased cardiac work relative to pioglitazone (P=0.006), a change that was paralleled by a reduced myocardial glucose uptake and fatty acid oxidation. Neither treatment affected cardiac high-energy phosphate metabolism or triglyceride content. Only pioglitazone reduced hepatic triglyceride content (P<0.001).

Conclusions— In T2DM patients, pioglitazone was associated with improvement in some measures of left ventricular diastolic function, myocardial glucose uptake, and whole-body insulin sensitivity. The functional changes, however, were not associated with myocardial substrate and high-energy phosphate metabolism.

---

 

CLINICAL PERSPECTIVE

Related Article:

Clinical Summaries
Circulation 2009 119: 2017-2019. [Extract] [Full Text]

This article has been cited by other articles:

				L. H. Opie and J. Knuuti The adrenergic-Fatty Acid load in heart failure. J. Am. Coll. Cardiol., October 27, 2009; 54(18): 1637 - 1646. [Abstract] [Full Text] [PDF]

				R. J. Gropler Lost in Translation: Modulation of the Metabolic-Functional Relation in the Diabetic Human Heart Circulation, April 21, 2009; 119(15): 2020 - 2022. [Full Text] [PDF]